Synta Pharmaceuticals Corp. is now in Oversold Territory - Tale of the Tape


Shutterstock photo

Synta Pharmaceuticals Corp.'s ( SNTA ) share price has entered into oversold territory with an RSI value of 26.6. The Zacks Consensus Estimate on Synta Pharmaceuticals Corp.'s earnings for the full year period has loss of 0.02 cents over the past two months to $-1.18 per share. Currently, Synta Pharmaceuticals Corp. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( SNTA ) after its recent drop.

SYNTA PHARMACT (SNTA): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by